Erica Ginsburg, Umer Khan, Phillip Pham, Anmol Kundlas, Simran Gill
Epidemiological data and recent scientific publications provide support for the neuroprotective effects of coffee against AD(1). The proposed mechanisms of therapeutic benefits include inhibition of an enzyme known as alpha secretase which results in lower levels of Amyloid beta plaques and increase in a hematopoietic factor known as GCSF(2). The aim of this study is to find the amount of coffee and type of coffee which ensures cell survival while reducing amyloid beta levels. N2APP are neuroblastoma cells from the APPsw mouse model with mutated genes for developing Alzheimer’s disease. N2APP cells can be treated
with various drugs and the cytotoxicity of these drugs on their neurons can be measured using MTT assay. The survival rate of cells at various concentrations of coffee treatment can be quantified. 24 hours after drug treatment, the supernatant was collected, and amyloid beta levels were measured using ELISA. The data in this study is based on treatment of N2APP cells with Instant coffee and common commercial coffee solutions.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License
BrainXell's human neuron culture platforms provide a means to model the human brain in a dish and perform in vitro functional assays. This system enables the screening of disease phenotypes and pharmacological agents that alter neuronal activity.
Download this poster to learn how an adapted version of PEAKS™ enables identifications and label-free quantification from PASEF runs and enhances the speed, sensitivity and selectivity of label-free quantification.